John Harry III Cross
CIK 1806763 · Chief Financial Officer · last filed 2025-03-11
John Harry III Cross is a Chief Financial Officer who has filed 6 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for SNTI, was dated Mar 11, 2025.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
6
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SNTI | Chief Financial Officer | — | $0.96 | — | $0 | 1 | 2025-03-11 |
| Sonnet BioTherapeutics Holdings, Inc. (SONN) Delisted | Chief Financial Officer | 1,588 | $1.26 | $2.0K | $0 | 5 | 2024-12-05 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-11 | SNTI | Grant (A) | — | $0 | EDGAR |
| 2024-12-05 | Sonnet BioTherapeutics Holdings, Inc. (SONN) Delisted | Grant (A) | −1,452 | $0 | EDGAR |
| 2023-02-17 | Sonnet BioTherapeutics Holdings, Inc. (SONN) Delisted | Tax (F) | −1,960 | -$2.1K | EDGAR |
| 2022-12-22 | Sonnet BioTherapeutics Holdings, Inc. (SONN) Delisted | Grant (A) | +15,519 | $0 | EDGAR |
| 2022-04-08 | Sonnet BioTherapeutics Holdings, Inc. (SONN) Delisted | Grant (A) | +66,951 | $0 | EDGAR |
| 2020-07-02 | Sonnet BioTherapeutics Holdings, Inc. (SONN) Delisted | Grant (A) | +78,214 | $0 | EDGAR |